8-K: Revelation Biosciences Reports Q2 2025 Results

Revelation Biosciences, a clinical-stage life sciences company, reported its financial results for the three and six months ended June 30, 2025, highlighting reduced net losses and progress in its Gemini clinical program.

Summary

• Cash and cash equivalents were $5.2 million as of June 30, 2025, a decrease from $6.5 million as of December 31, 2024.
• Net cash used for operating activities for the three months ended June 30, 2025, was $4.7 million, an improvement from $5.3 million for the same period in 2024.
• Net loss for the three months ended June 30, 2025, was $2.4 million, or $(7.01) basic and diluted net loss per share, significantly reduced from $8.4 million, or $(246.27) per share, for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $4.5 million, or $(13.60) basic and diluted net loss per share, reduced from $11.1 million, or $(390.02) per share, for the same period in 2024.
• The company completed dosing of patients in its PRIME Phase 1b Clinical Study of Gemini in CKD Patients.
• Revelation Biosciences received gross proceeds of $4 million from a public offering in May 2025.
• Management believes current cash and cash equivalents are sufficient to fund operations through December 2025.

Sentiment

Score: 7

Explanation: The company reported a significant reduction in net losses and cash burn compared to the prior year, indicating improved financial management. Clinical progress with the completion of dosing in a Phase 1b study and a recent capital raise are positive operational and financial milestones. However, the company remains in a net loss position with limited cash runway (through December 2025), and future success is highly dependent on clinical trial outcomes and regulatory approvals, which carry inherent risks.

Positives

• Net loss significantly decreased for both the three and six months ended June 30, 2025, compared to the prior year periods, indicating improved financial performance.
• Net cash used for operating activities decreased to $4.7 million in Q2 2025 from $5.3 million in Q2 2024, showing a reduction in cash burn.
• Successful completion of patient dosing in the PRIME Phase 1b Clinical Study of Gemini in CKD Patients marks a significant clinical development milestone.
• The company secured $4 million in gross proceeds from a public offering in May 2025, bolstering its financial resources.
• Management projects that current cash and cash equivalents are sufficient to fund operations through December 2025.

Negatives

• Cash and cash equivalents decreased to $5.2 million as of June 30, 2025, from $6.5 million as of December 31, 2024, indicating continued depletion of cash reserves.
• The company continues to operate at a net loss, reporting $2.4 million for Q2 2025 and $4.5 million for the first six months of 2025.
• The projected cash runway extends only through December 2025, suggesting a need for further capital in the near future.

Risks

• The ability of Revelation to meet its financial and strategic goals may be adversely affected by competition.
• Challenges exist in the company's ability to grow and manage growth profitably and retain its key employees.
• Revelation may be adversely affected by other economic, business, and/or competitive factors.
• Risks are associated with the successful development of Revelation's product candidates.
• The ability to successfully complete planned clinical studies of its product candidates is not guaranteed.
• There is a risk that clinical studies may not be fully enrolled or enrollment will take longer than expected.
• Risks relate to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from clinical studies.
• Changes in applicable laws or regulations could negatively impact the company.
• Uncertainty exists regarding the expected initiation of clinical studies and the timing of clinical data.
• The outcome of clinical data, including whether the results are positive or can be replicated, is uncertain.
• The anticipated treatment of future clinical data by regulatory authorities (FDA, EMA), including whether such data will be sufficient for approval, is a risk.
• The success of future development activities for its product candidates is not assured.
• Potential indications for which product candidates may be developed carry inherent risks.
• The ability of Revelation to maintain the listing of its securities on NASDAQ is a factor.
• The expected duration over which Revelation's balances will fund its operations is subject to change.

Future Outlook

Revelation Biosciences expects to announce data from its Phase 1b study of Gemini later in Q3 2025 and plans to engage with the FDA later in 2025 to advance the clinical development of the Gemini program. The company projects its current cash and cash equivalents will fund operations through December 2025.

Management Comments

• "The Revelation team continues to strategically maximize its financial resources to achieve our stated objectives and advance the Gemini program."
• "We look forward to announcing data from the Phase 1b study later this quarter and engaging with the FDA later this year to further the clinical development of Gemini and enhance shareholder value."

Industry Context

Revelation Biosciences operates in the highly competitive clinical-stage life sciences sector, specifically focusing on rebalancing inflammation through its proprietary Gemini formulation. The company's progress in its Phase 1b clinical study for Chronic Kidney Disease (CKD) and other indications positions it within the broader trend of developing novel therapies for inflammatory and immune-mediated diseases. Success in clinical trials and regulatory engagement are critical milestones in this industry, often determining a company's valuation and future prospects.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Potential for increased value if clinical trials are successful and regulatory milestones are met; dilution from recent public offering; continued risk due to ongoing losses and limited cash runway.
• Employees: Continued employment and focus on advancing the Gemini program.
• Customers (future patients): Potential for new therapeutic options for conditions like CKD, AKI, and post-surgical infections if Gemini is successfully developed and approved.
• Creditors/Suppliers: Ongoing operational activities suggest continued engagement, but financial health remains a factor.

Next Steps

• Announce data from the Phase 1b study later in Q3 2025.
• Engage with the FDA later in 2025 to further the clinical development of Gemini.

Key Dates

Recommendation

While Revelation Biosciences demonstrated improved financial performance with reduced net losses and cash burn, and achieved a key clinical milestone by completing dosing in its Phase 1b study, the company remains pre-revenue with a limited cash runway through December 2025. The recent $4 million capital raise provides some liquidity but future funding will likely be required. The stock's performance is highly contingent on the upcoming Phase 1b data announcement and subsequent FDA engagement. Given the significant clinical risks inherent in a clinical-stage biotech and the short cash runway, a 'hold' recommendation is appropriate. Investors should await the Phase 1b data and further clarity on the company's long-term funding strategy before making a more definitive investment decision.

Keywords

Revelation Biosciences, REVB, Biotechnology, Clinical Stage, Life Sciences, Inflammation, Gemini, CKD, Acute Kidney Injury, Post-Surgical Infection, SEC Filing, Financial Results, NASDAQ